APRI、CDS指数在乙肝相关性肝癌中的应用

发布时间：2018-03-11 02:08

本文选题：肝肿瘤　切入点：无创诊断　出处：《实用医学杂志》2015年07期 　论文类型：期刊论文

【摘要】：目的:本研究应用血小板(PLT)比值指数(AST/PLT ratio index,APRI)和肝纤维化无创诊断横型(cirrhosis discriminant score,CDS)指数对乙肝相关性肝癌患者进行检测,探讨其对肝癌纤维化评估的价值。方法:将145例确诊为肝癌的患者根据手术所见及肝组织病理结果确定有无肝硬化,再根据是否合并有乙肝病毒感染进行分组,每例患者同时进行APRI、CDS指数评估,比较无创诊断模型与肝硬化的相关性,并根据受试者工作特征曲线(ROC)分析无创诊断模型对乙肝相关性肝癌的肝纤维化的诊断价值。结果:APRI、CDS指数无创诊断方法与肝硬化具有良好的一致性,Spearman相关系数分别为:合并乙肝患者为0.252(P=0.035)和0.269(P=0.024),未合并乙肝患者为0.487(P=0.006)和0.541(P=0.002)。APRI和CDS诊断肝硬化的曲线下面积(ROC)合并乙肝患者分别为0.611和0.640,未合并乙肝患者分别为0.714和0.728。结论:APRI和CDS均能预测肝癌患者肝硬化程度,其中对于未合并乙肝的肝癌患者预测价值更高。
[Abstract]:Objective: to study the application of the platelet / PLT ratio index (AST / PLT ratio index) and the noninvasive diagnosis of hepatic fibrosis in patients with Hepatitis B related hepatocellular carcinoma (HBV-related liver cancer) by using the index of cirrhosis discriminant score#en0# (CDSs). Methods: 145 patients with liver cancer diagnosed as liver cancer were divided into two groups according to the surgical findings and pathological findings of liver tissue to determine the presence of liver cirrhosis, and then according to whether they were complicated with hepatitis B virus infection. Each patient was evaluated with APRI CDS index at the same time, and the correlation between noninvasive diagnosis model and cirrhosis was compared. The diagnostic value of non-invasive diagnostic model for hepatic fibrosis in Hepatitis B related liver cancer was analyzed according to the operating characteristic curve of the subjects. Results the non-invasive diagnostic method of CDS index in the case of Hepatitis B associated with Hepatitis B was in good agreement with the Spearman correlation coefficient of liver cirrhosis. In patients with hepatitis B, it was 0.252 and 0.640) and in patients without hepatitis B, it was 0.714 and 0.728, respectively. Conclusion: in patients with hepatitis B, it was 0.487P0. 006) and in patients with hepatitis B, the area under the curve of CDS for diagnosing cirrhosis was 0. 611 and 0. 640, respectively. Conclusion\% APRI and CDS can be used in the diagnosis of liver cirrhosis, respectively, and 0. 714 and 0. 728 in the patients without hepatitis B. conclusion\% APRI and CDS can be used in the diagnosis of liver cirrhosis. The degree of liver cirrhosis in patients with liver cancer was measured. The predictive value for HCC patients without hepatitis B was higher.
【作者单位】：南方医科大学附属顺德第一人民医院;
【基金】：广东省科学技术厅社会发展项目(编号:2010B031500003)
【分类号】：R512.62;R735.7

【参考文献】